IP Library Granted Patent US 7,425,544
Granted Patent B2
US 7,425,544 · App. 10/571,339 · Granted Sep 16, 2008

Modulation of eIF4E expression

Assignees: Eli Lilly and Company; ISIS Pharmaceuticals, Inc.
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 7,425,544
App. No.
10/571,339
Granted
Sep 16, 2008
Kind
B2
Abstract

Oligomeric compounds, compositions and methods are provided for modulating the expression of eIF4E. The antisense compounds may be single- or double-stranded and are targeted to nucleic acid encoding eIF4E. Methods of using these compounds for modulation of eIF4E expression and for diagnosis and treatment of diseases and conditions associated with expression of eIF4E are provided.

Claims (16)

1. A modified antisense oligonucleotide, comprising the nucleotide sequence shown in SEQ ID NO:40, having at least one chemically modified internucleoside linkage, sugar moiety, or nucleobase, or a pharmaceutically acceptable salt thereof.

2. The modified antisense oligonucleotide or pharmaceutically acceptable salt thereof of claim 1 , which consists of 20 to 30 nucleotides.

3. The modified antisense oligonucleotide or pharmaceutically acceptable salt thereof of claim 1 , having at least one 2′-O-(2-methoxyethyl) sugar moiety.

4. The modified antisense oligonucleotide or pharmaceutically acceptable salt thereof of claim 1 , having at least one phosphorothioate internucleoside linkage.

5. The modified antisense oligonucleotide or pharmaceutically acceptable salt thereof of claim 1 , wherein at least one cytosine is a 5-methylcytosine.

6. The modified antisense oligonucleotide or pharmaceutically acceptable salt thereof of claim 1 , wherein every internucleoside linkage is a phosphorothioate linkage, nucleotides 1-5 and 16-20 reading from the 5′ end to the 3′ end of SEQ ID NO:40 each comprise a 2′-O-(2-methoxyethyl) sugar, nucleotides 6-15 are 2′-deoxynucleotides, and every cytosine residue is a 5-methylcytosine.

7. The modified antisense oligonucleotide or pharmaceutically acceptable salt thereof of claim 1 , which is in the form of a sodium salt.

8. A modified antisense oligonucleotide, consisting of the nucleotide sequence shown in SEQ ID NO:40, wherein every internucleoside linkage is a phosphorothioate linkage, nucleotides 1-5 and 16-20 reading from the 5′ end to the 3′ end each comprise a 2′-O-(2-methoxyethyl) sugar, nucleotides 6-15 are 2′-deoxynucleotides, and every cytosine residue is a 5-methylcytosine, which modified antisense oligonucleotide is in the form of a sodium salt.

9. A pharmaceutical or veterinary composition, comprising said sodium salt of said modified antisense oligonucleotide of claim 8 , and a pharmaceutically or physiologically acceptable carrier, diluent, or excipient.

10. A method of treating a condition or disease associated with eIF4E expression or overexpression in a mammal in need thereof, comprising administering to said mammal an effective amount of said sodium salt of said modified antisense oligonucleotide of claim 8 .

11. The method of claim 10 , wherein said condition or disease associated with eIF4E expression or overexpression is a hyperproliferative condition or disease.

12. The method of claim 11 , wherein said hyperproliferative condition or disease is a susceptible cancer, tumor, or condition characterized by aberrant angiogenesis.

13. The method of claim 11 , wherein said hyperproliferative condition or disease associated with eIF4E expression or overexpression is selected from the group consisting of breast cancer, head and neck cancer, colorectal cancer, prostate cancer, lung cancer, bladder cancer, ovarian cancer, renal cancer, and glioblastoma.

14. The method of claim 10 , wherein said mammal is a human.

15. A modified antisense oligonucleotide, consisting of the nucleotide sequence shown in SEQ ID NO:40, having at least one chemically modified internucleoside linkage, sugar moiety, or nucleobase, which modified antisense oligonucleotide is in the form of a sodium salt.

16. A The modified antisense oligonucleotide of claim 15 , wherein every internucleoside linkage is a phosphorothioate linkage, nucleotides 1-5 and 16-20 reading from the 5′ end to the 3′ end each comprise a 2′ -O-(2-methoxyethyl) sugar, nucleotides 6-15 are 2′-deoxynucleotides, and at least one cytosine is a 5-methylcytosine, and which modified antisense oligonucleotide is in the form of a sodium salt.

Assignments (2)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jan 15, 2010
From: ELI LILLY AND COMPANY
To: ISIS PHARMACEUTICALS, INC.
Reel/Frame 023792/0639 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded May 6, 2008
From: FREIER, SUSAN M.; DOBIE, KENNETH W.; MARCUSSON, ERIC G.; SWAYZE, ERIC E.; BHAT, BALKRISHEN
To: ISIS PHARMACEUTICALS, INC.
Reel/Frame 020907/0137 →
Continuity (1)
Related Publication 20070066549A1 · Mar 22, 2007